A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

Completed

• Conditions: Malignant Lymphoma; Clinical Trial; COVID-19

• Registration Number: NCT05827341
• Lead Sponsor: Sun Yat-sen University

Brief Summary

This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-01
• Primary Completion: 2023-01-31
• Study First Submitted: 2023-04-22
• Study First Submitted QC: 2023-04-22
• Study First Posted: 2023-04-25
• Study Completion: 2023-05-15
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-15
• Last Update Posted: 2023-06-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

(1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available.

Exclusion Criteria

• Patients who could not provide detailed information about COVID-19 infection.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The severity of COVID-19	2 months	The severity of COVID-19 infection in maligant lymphoma patients evaluated by investigators
Hospital admission rate of COVID-19 infection	2 months	The percentage of malignant lymphoma patients who were admitted into hospital

Trial Locations

Locations (1)

Department of Medical Oncology, Sun Yat-Sen University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China